IMDX Insight Molecular Diagnostics I
$4.20▲ +5.53%
Healthcare
Other
After hours
$4.05▼ -3.57%
Sep 11, 7:40 PM ET
Volume 173.6K
Avg Volume (10D) 144.1K
Key Metrics & Fundamentals
Market Cap
$137.44M
P/E Ratio
–
Div Yield
–%
52W Range
2.42 - 8.51
% vs 50 MA
-7.87%
% vs 200 MA
-19.31%
RSI-14
47.3
MACD Histogram
+0.0200
Beta (1Y vs SPY)
2.51
Free Cash Flow
-$10.05M
Gross Rev
$239,000
Gross Profit
$157,000
EBITDA
-$8.26M
COGS
$82,000
Operating Exp
$9.25M
Operating Income
-$9.09M
EBIT
-$9.09M
Pretax Income
-$11.26M
Net Income
-$11.26M
EPS (Diluted)
-0.31
Price & Volume History
Loading chart…
Recent News
iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference
GlobeNewswire · Sep 2, 2026 12:00 PM
Insight Molecular Diagnostics (IMDX) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 17, 2026 9:28 PM
Oncocyte Eyes Faster, Less Invasive Heart Transplant Rejection Testing
MarketBeat · Aug 17, 2026 6:02 PM
Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing
GlobeNewswire · Aug 11, 2026 8:05 PM
Insight Molecular Diagnostics Inc. Q2 2026 Earnings Call Summary
Moby · Aug 11, 2026 12:30 PM
Oncocyte Q2 Earnings Call Highlights
MarketBeat · Aug 11, 2026 12:04 AM
Insight Molecular Diagnostics: Q2 Earnings Snapshot
Associated Press · Aug 10, 2026 8:39 PM
IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
GlobeNewswire · Aug 10, 2026 8:05 PM
iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference
GlobeNewswire · Aug 4, 2026 11:00 AM
iMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group Publication
GlobeNewswire · Jul 23, 2026 12:00 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See IMDX's money flow as a full page
Social Sentiment
No Reddit posts found for IMDX.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.